Logotype for Straumann Holding AG

Straumann Group (STMN) Q2 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Straumann Holding AG

Q2 2024 earnings summary

1 Feb, 2026

Executive summary

  • H1 2024 revenue reached CHF 1.3 billion, with 16.1% organic growth and Q2 revenue at CHF 655 million, reflecting strong double-digit growth and market share gains across all regions despite currency headwinds.

  • Core EBIT margin was 27.8% (28.9% at constant FX), and core net profit from continuing operations was CHF 282 million, with basic EPS at CHF 1.76.

  • The sale of DrSmile to Impress Group, with a 20% minority stake retained, led to restated financials and sharpened focus on B2B orthodontics and digital transformation.

  • Innovation and education initiatives included the launch of new digital solutions (UN!Q, SIRIOS scanner, iEXCEL implant system) and the ITI World Symposium in Singapore.

  • Executive management changes included new appointments and retirements in key leadership, HR, and technology roles.

Financial highlights

  • H1 2024 revenue: CHF 1,273.3 million (up 11.3% in CHF, 16.1% organic year-over-year); Q2 revenue: CHF 655 million.

  • Core gross margin: 72.5% (down 180bps year-over-year due to mix and FX); IFRS gross margin: 72.1%.

  • Core EBIT margin: 27.8% (up 70bps currency-adjusted, down 120bps year-over-year); IFRS EBIT margin: 26.4%.

  • Core net profit: CHF 282 million (22.2% margin); IFRS net profit: CHF 268.2 million (21.1% margin); core basic EPS: CHF 1.76 (up from CHF 1.59).

  • Free cash flow: CHF 145 million (11.4% of revenue); cash position at end-June: CHF 334 million.

Outlook and guidance

  • 2024 organic revenue growth expected in the low double-digit percentage range, with profitability in the 27–28% range at constant 2023 FX rates.

  • Guidance upgrade reflects DrSmile divestiture and better-than-expected core business performance, especially in EMEA and APAC.

  • H2 growth expected to decelerate due to tougher comps in China and a higher base effect.

  • 2030 ambition for CHF 5 billion revenue reaffirmed, with double-digit growth expected and possible business mix shifts.

  • Global patient flow anticipated to remain stable despite economic uncertainty.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more